In this medfyle

Menin inhibitors represent an exciting advance in the treatment of AML, specifically targeting KMT2A-rearranged and NPM1-mutated subtypes. By disrupting menin's role in oncogenic transcription, these innovative agents have shown significant promise in providing durable remissions even in relapsed and refractory AML patients. With a favorable safety profile and ongoing trials combining menin inhibitors with other therapies, this class of drugs is set to transform the therapeutic landscape of AML, offering new hope to a challenging patient population.